Answers are grounded in this paper and cite their sources.
Acalabrutinib therapy leads to bilateral serous maculopathy in chronic lymphocytic leukemia, suggesting a need for therapy adjustment.
The bilateral, reversible serous maculopathy tightly linked to acalabrutinib exposure supports a drug-related etiology. BTK inhibitors should be considered in cases of new bilateral serous SRF/PEDs, and prompt coordination with oncology may facilitate recovery through systemic therapy modification.
No takes yet. Share an insight, caveat, or question.
Abbasgholizadeh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: